Data Management Excellence – What it Takes
What Data Managers Do
Gathering, analyzing, and presenting the data to support life-altering new medicines for people around the world is a long, complex, and detailed proces
Securing VC Funding and Drug Manufacturing Consulting
Consultant Series ― Interview with Teresa Johnk
Listen in as we discuss the role of a strategic business development consultant in drug development with industry veteran Teresa Johnk, Founder and CEO of BioPharma Connections.
In this podcast, we uncover:
- Important considerations to secure VC funding
- How to ensure the successful program completion
- What to look for in a consultant
- What to look for in a CRO/CDMO partner
Connect with our industry experts.
You may also be interested in the following:
- Webinar: Overcoming the Challenges of Manufacturing and Clinical Trials
- Factsheet: Manufacturing and Analytical Services
- Webpage: Full-Time Equivalent (FTE) Capabilities
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.
Scientific Project Management — We Lead With Your Priorities in Mind
A Seamless Experience, Thanks to Expert Scientific Project Management
From lead candidate selection to clinical proof of concept, whether for a single study or multiple programs, Altasciences’ Scientific Project Management team manages every study with your business priorities in mind.
Join Lauren Szczurowski, Executive Director of Scientific Project Management, in this on-demand podcast as she reveals how Altasciences makes outsourcing early phase drug development a seamless experience.
Schedule a conversation with one of our Scientific Project Managers to review your questions and requirements.
You may also be interested in the following:
- Video: The Benefits of Tell Us Once™
- Video: Your Road to Proactive Development with Altasciences
- Fact Sheet: First-in-Human Trial Capabilities
- Webpage: Full-Time Equivalent Capabilities
The Lancet Covers Altasciences’ Contribution to Research for Weight Management
A Look into Weight Management Research
Altasciences’ Medical Director and Investigator, Dr. Martin Kankam, M.D., PhD, MPH, along with a team of scientific experts, have successfully investigated the safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2•4 mg for weight management, in a randomized, controlled, Phase Ib trial.
Access the full article co-authored by Dr. Kankam to learn about the findings, methods, and results of this trial.
As experts in the field, we have conducted over 75 early stage trials involving antidiabetic and hypoglycemic agents in patients who are diabetic (Type 1 and 2), obese, or have metabolic syndrome or NASH. These include a large number of proof-of-concept studies investigating different measures of glucose tolerance, including clamping studies using the state-of-the-art YSI 2950D biochemistry analyzer to efficiently process multiple glucose samples per run.
Speak with a metabolic disorder expert today.
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.
You may also be interested in:
- The Altascientist: The Global Challenge of Metabolic Disorders
- Fact Sheet: First-in-Human Capabilities
- Webpage: Proof-of-Concept Capabilities
- Press Release: Altasciences Qualifies Quantitative Serological Assay for the Detection of SARS-CoV-2 IgG Antibodies
- Press Release: WCCT Global (an Altasciences Company) Clinic Expansion
MedPage Today: Amylin Analogue Plus Semaglutide Get Early Win for Weight Loss
Altasciences Initiates Phase I Study in Healthy Normal Subjects for ST-2427, a Non-Opioid Analgesic for Acute Pain
Laval, Quebec, May 13, 2021 – Altasciences is pleased to support SiteOne Therapeutics with a Phase I, randomized, double-blind, placebo-controlled study in healthy adults to evaluate the safety, tolerability, and pharmacokinetics of ST-2427. ST-2427 is a highly selective inhibitor of NaV1.7 for the management of moderate-to-severe pain; by selectively targeting NaV1.7, ST-2427 aims to stop the electrical signals responsible for pain before they reach the central nervous system.
Amy Denvir, General Manager of Altasciences’ Kansas City clinical site, says, “We are proud to partner with SiteOne Therapeutics and help move this important therapeutic into clinical trials. Helping bring to market a new approach that may provide a non-opioid option to treat moderate to severe pain is an exciting prospect, and we look forward to delivering this ground-breaking research.”
Click here to read the SiteOne press release.
Altasciences has designed and conducted hundreds of first-in-human trials by offering comprehensive, full service, early development solutions. With a focus on developing sound strategies combined with operational efficiencies, the company minimizes the time taken to make critical go/no-go decisions by harmonizing clinical pharmacology services, biomarker capabilities, PK/PD analysis expertise, and program knowledge.
About Altasciences
Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.
CONTACT:
Julie-Ann Cabana
Altasciences
514 601-9763
jcabana@altasciences.com
Effect of Difelikefalin, a Selective Kappa Opioid Receptor Agonist, on Respiratory Depression: A Randomized, Double-Blind, Placebo-Controlled Trial